Ohio Patent of the Month – July 2024
MediSync Inc. is using artificial intelligence (AI) to improve hypertension treatments. Thanks to their development efforts, the company has secured a patent, outlining how this solution could be used to manage heart failure treatments, transforming patient care through precision and efficiency. This innovative technology leverages artificial intelligence to tailor pharmaceutical prescriptions based on real-time patient data, optimizing outcomes for heart failure patients.
At the core of MediSync’s invention is an advanced AI application integrated with electronic medical records (EMR) systems. It gathers comprehensive patient information, including historical data and current conditions, and validates this data through input from medical professionals. The system employs specialized pharmaceutical models and an expert system to predict patient responses to different medications, enabling highly personalized treatment plans.
The AI application uses pharmaceutical-specific models for various drug classes, such as ACE inhibitors, beta-blockers, and MRAs. By inputting patient-specific data into these models, the system predicts changes in the patient’s condition in response to different dosages. It then selects the most appropriate drug classes and calculates optimal dosages, prioritizing them based on their predicted effectiveness and safety.
One of the key features of MediSync’s solution is its rule-based expert system, which applies over 250 rules to ensure precise and safe medication adjustments. This system evaluates factors like heart rate, fluid flow, and other critical health indicators to refine treatment recommendations. The result is an updated prescription that is continuously refined as new data becomes available, ensuring that the treatment remains aligned with the patient’s evolving needs.
MediSync’s AI system also supports complex scenarios, such as translating dosages between different drug classes and adjusting prescriptions based on various health metrics. This adaptability makes it an invaluable tool for clinicians, helping them manage the intricate balance of medications required for heart failure patients.
By harnessing the power of AI, MediSync is setting a new standard in personalized healthcare, enhancing the ability of medical professionals to deliver precise, data-driven treatments and improve patient outcomes significantly.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
